Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Pfizer and Scil finalize agreement for novel cartilage growth factor


NEW YORK and Martinsried, Germany, January 16, 2008 -- Pfizer Inc (NYSE:PFE) and Scil Technology GmbH (Scil) have signed a licensing agreement for worldwide collaboration on Scil’s cartilage specific growth factor CD-RAP. Under this agreement, Pfizer will obtain a worldwide exclusive license to develop and commercialize CD-RAP. In addition to receiving royalties on the sale of any products that may be commercialised under this agreement, Scil is eligible for upfront and milestone payments of approximately US $250 million depending on the achievement of various development and regulatory milestones.

“The successful conclusion of this license agreement with Pfizer increases the company’s value”, stated Dr. Weishui Weiser, managing director of Scil. “In addition, this is one more step towards achieving Scil’s mission, improving the quality of patients’ lives.”

“We are pleased”, added Dr. Volker Lang, vice president, Corporate Development of Scil. ”We believe that having Pfizer as a partner advances Scil as an organisation capable of generating commercial value from scientific expertise.”

“This partnership reflects Pfizer’s ongoing commitment to pursue the best science anywhere on the globe and secure novel technologies and products that will complement our existing research programs,” said Dr. Edmund Harrigan, senior vice president Worldwide Business Development. “We look forward to working with Scil on this collaboration and leveraging our combined resources to develop valuable new treatment options for patients with osteoarthritis.”

About Pfizer
Pfizer discovers and develops innovative medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and to provide better quality healthcare and health system support.

About Scil Technology GmbH

Scil Technology is a privately financed biopharmaceutical development company focused on dental and orthopedic tissue regeneration with a particular emphasis on bone and cartilage repair. The company’s therapeutic candidates are based on recombinant human growth factors. These factors are combined with biodegradable biomaterials to generate local application forms. Scil Technology’s pipeline for dentistry includes products that are targeted at periodontal disease, dental implantology and maxillofacial surgery. Orthopedic products are developed for treatment of traumatic lesions of bone and cartilage and osteoarthritis. Scil Technology is located in the biotechnology cluster in Martinsried, Germany.

For more information on Pfizer or Scil Technology, please visit www.pfizer.com or www.sciltechnology.com .

# # # # #

Scil Technology GmbH Contacts:

Douglas Pretsell
t: +49 (0)89 5700 1806
douglas.pretsell@collegehill.com


Dr. Volker Lang
t: +49 (0)89 8565 1800

m: +49 (0)172 8983 311
volker.lang@sciltechnology.com

Pfizer Contacts:

Shreya Jani

t: +1 (212)733 4889 (media)

Jennifer Davis
t: +1 (212)733 0717 (investors)


Publisher Contact Information:

Scil Technology GmbH
+49 (0)172 8983 311
volker.lang@sciltechnology.com

Company profile of Scil Technology GmbH
Past press releases of Scil Technology GmbH.

Data


26,416
Tech investments
From our Online Data Service
17,054
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 30€3.6MSoftware development
Nov 29€3.6MBiopharmaceuticals
Nov 28N/ABiotechnology
Nov 28N/ABusiness applications
Nov 28€12.0MPublishing
Nov 28N/AeLearning
Nov 28€7.6MSensors

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.